NASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $50.35 +0.15 (+0.30%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$48.72▼$51.0150-Day Range$41.27▼$50.8252-Week Range$25.60▼$77.60Volume110,854 shsAverage Volume366,147 shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$64.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Disc Medicine alerts: Email Address Disc Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside27.4% Upside$64.13 Price TargetShort InterestBearish8.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 2 Articles This WeekInsider TradingSelling Shares$8,731 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.19) to ($4.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.55 out of 5 starsMedical Sector636th out of 910 stocksPharmaceutical Preparations Industry289th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingDisc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDisc Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Disc Medicine's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.72% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Disc Medicine has recently decreased by 0.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRON. Previous Next 1.8 News and Social Media Coverage News SentimentDisc Medicine has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Disc Medicine this week, compared to 3 articles on an average week.Search Interest12 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,731.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.19) to ($4.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -14.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -14.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Disc Medicine Stock (NASDAQ:IRON)Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Read More IRON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRON Stock News HeadlinesSeptember 4 at 2:03 AM | americanbankingnews.comDisc Medicine, Inc. (NASDAQ:IRON) Receives $64.13 Consensus Target Price from AnalystsAugust 30, 2024 | globenewswire.comDisc Medicine to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 28, 2024 | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Earns Overweight Rating from Analysts at Wells Fargo & CompanyAugust 28, 2024 | americanbankingnews.comWells Fargo & Company Begins Coverage on Disc Medicine (NASDAQ:IRON)August 23, 2024 | msn.comIron metabolism could be targeted to treat an aggressive form of cancer, study suggestsAugust 23, 2024 | msn.comWells Fargo Initiates Coverage of Disc Medicine (IRON) with Overweight RecommendationAugust 22, 2024 | markets.businessinsider.comOptimistic Outlook on Disc Medicine’s Pipeline and Investment PotentialSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 17, 2024 | msn.comBlack Myth: Wukong review – "A great action RPG that feels like God of War for Chinese mythology"August 17, 2024 | msn.comThe Best Loot You Can Find In Trial Chambers In MinecraftAugust 15, 2024 | msn.comStudy finds over half of iron deficiency cases in large health system still unresolved at three yearsAugust 10, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn SituationAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Disc Medicine’s Strong Clinical Pipeline and Financial HealthAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Disc Medicine on Strong Financials and Positive Clinical TrialsAugust 8, 2024 | finance.yahoo.comDisc Medicine Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | markets.businessinsider.comIRON Stock Earnings: Disc Medicine Beats EPS for Q2 2024August 7, 2024 | msn.comShould you use 'convertor discs' on induction cooktops? We asked the expertsSee More Headlines Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CUSIPN/A CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$64.13 High Stock Price Target$85.00 Low Stock Price Target$40.00 Potential Upside/Downside+27.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.78% Return on Assets-22.62% Debt Debt-to-Equity RatioN/A Current Ratio25.02 Quick Ratio25.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$16.44 per share Price / Book3.06Miscellaneous Outstanding Shares24,722,000Free Float23,674,000Market Cap$1.24 billion OptionableNot Optionable Beta0.59 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. William Jacob Savage M.D. (Age 49)Ph.D., Chief Medical Officer Comp: $687.74kDr. John D. Quisel Esq. (Age 53)J.D., Ph.D., CEO, President & Director Comp: $750.12kDr. Brian MacDonald ChB (Age 64)MB, Ph.D., Founder & Chair of Scientific Advisory Board Comp: $88.54kMs. Jean M. Franchi (Age 58)Chief Financial Officer Mr. Jonathan Yu M.B.A. (Age 43)Chief Opearating Officer Comp: $539.32kDr. Rahul Khara J.D. (Age 42)Pharm.D., General Counsel, Compliance Officer & Secretary Mr. Srikanth Venkatraman Ph.D.Senior VP & Head of ChemistryMs. Hua Yang Ph.D.Senior Vice President of Nonclinical DevelopmentMs. Pamela Stephenson M.P.H. (Age 55)Chief Commercial Officer Ms. Sonia Razzetti Ph.D.Senior VP of QualityMore ExecutivesKey CompetitorsArdelyxNASDAQ:ARDXLiquidiaNASDAQ:LQDALandsea HomesNASDAQ:LSEACabaletta BioNASDAQ:CABAQuantum-SiNASDAQ:QSIView All CompetitorsInsiders & InstitutionsTeachers Retirement System of The State of KentuckyBought 14,102 shares on 8/26/2024Ownership: 0.057%Nantahala Capital Management LLCBought 150,000 shares on 8/20/2024Ownership: 0.607%Frazier Life Sciences Management L.P.Bought 969,834 shares on 8/16/2024Ownership: 7.098%Perceptive Advisors LLCSold 86,429 shares on 8/16/2024Ownership: 2.239%Algert Global LLCBought 5,298 shares on 8/16/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $57.76 at the beginning of 2024. Since then, IRON stock has decreased by 12.8% and is now trading at $50.35. View the best growth stocks for 2024 here. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.11) by $0.08. Who are Disc Medicine's major shareholders? Top institutional shareholders of Disc Medicine include Atlas Venture Life Science Advisors LLC (10.15%), Frazier Life Sciences Management L.P. (7.10%), Deerfield Management Company L.P. Series C (4.14%) and Logos Global Management LP (3.74%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Brian Richard Macdonald, Joanne Bryce, Mona Ashiya, Rahul Khara and William Jacob Savage. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IRON) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.